Invivyd Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/14/24
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the EditorGlobeNewsWire • 11/14/24
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, RespectivelyGlobeNewsWire • 11/12/24
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation ConferenceGlobeNewsWire • 11/06/24
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024GlobeNewsWire • 11/06/24
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term ProfitabilityGlobeNewsWire • 10/29/24
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent ParticipantsGlobeNewsWire • 10/29/24
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024GlobeNewsWire • 10/16/24
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataGlobeNewsWire • 10/01/24
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)GlobeNewsWire • 09/23/24
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19GlobeNewsWire • 09/12/24
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™GlobeNewsWire • 09/04/24
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of InterestGlobeNewsWire • 09/03/24
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical TrialGlobeNewsWire • 08/27/24
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/14/24
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 08/12/24
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® IndexesGlobeNewsWire • 07/01/24
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 VariantsGlobeNewsWire • 06/14/24
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for SerialGlobeNewsWire • 05/31/24
